{"product_id":"sema-cag","title":"Sema+Cag","description":"\u003ch1 dir=\"ltr\"\u003e\u003cstrong\u003eSema+Cag (Semaglutide + Cagrilintide) 5 mg\/5 mg Research Peptide\u003c\/strong\u003e\u003c\/h1\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"180\"\u003e\n\u003ccol width=\"444\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlternate name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide + cagrilintide (Novo Nordisk develops this pairing as CagriSema; this vial is not CagriSema)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCompound class\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 receptor agonist (semaglutide) plus long-acting amylin analog (cagrilintide)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFormat\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSealed research vial containing both peptides (physical form stated on the label and COA)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStrength(s)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e5 mg semaglutide + 5 mg cagrilintide per vial\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSequence\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18 diacid-γGlu-AEEA-AEEA)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH (31 residues). Cagrilintide: C20 diacid-γGlu-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (37 residues, disulfide bridge between the two cysteines)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular formula\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide C187H291N45O59; cagrilintide C194H312N54O59S2\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMolecular weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide 4114 g\/mol; cagrilintide 4409 g\/mol (PubChem, computed)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCAS number\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide 910463-68-2; cagrilintide 1415456-99-3\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePurity\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eStated per lot on the Certificate of Analysis (both components)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eManufacturer\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePEPTYVA, Mexico\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is Sema+Cag?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSema+Cag is a PEPTYVA research vial that combines two peptides: semaglutide 5 mg and cagrilintide 5 mg. It is sold for laboratory research use only and is not a medicine. Semaglutide is a GLP-1 receptor agonist, and cagrilintide is a long-acting amylin analog.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNovo Nordisk is developing the same pairing as CagriSema, an investigational product. Sema+Cag is not CagriSema. It shares the two active molecules, but it is a separate research material made by PEPTYVA with its own lot documentation.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is the semaglutide and cagrilintide pairing studied?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe pairing is studied because it engages two hormone pathways at once: GLP-1 and amylin. Controlled studies compare the combination with each component alone to see how the two pathways interact in glycemic and body weight regulation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eSemaglutide: selective GLP-1 receptor agonist with a lysine side chain linked to a C18 fatty diacid\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eCagrilintide: long-acting amylin analog acylated at the N-terminus with a C20 fatty diacid\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eTypical research topics: amylin and incretin receptor pharmacology, appetite signaling, glucose regulation\u003c\/span\u003e\u003c\/li\u003e\n\u003cli dir=\"ltr\" aria-level=\"1\"\u003e\u003cspan\u003eStudy design feature: factorial comparisons against each single component and placebo\u003c\/span\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat does the current evidence show?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eControlled human studies exist, but the combination is still investigational. REDEFINE 1 (New England Journal of Medicine, 2025) randomized 3,417 adults with overweight or obesity and without diabetes to the combination, semaglutide alone, cagrilintide alone or placebo for 68 weeks. REDEFINE 2 (New England Journal of Medicine, 2025) enrolled 1,206 adults with type 2 diabetes and overweight or obesity for 68 weeks.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBoth phase 3 trials met their primary body weight endpoints versus placebo. Gastrointestinal adverse events, such as nausea, vomiting, diarrhea and constipation, were frequent in both trials and mostly mild to moderate. No direct evidence exists for this specific PEPTYVA vial, as opposed to the sponsor's investigational product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow does Sema+Cag differ from semaglutide alone?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSemaglutide alone acts only on the GLP-1 receptor and is the active ingredient in approved branded medicines. Sema+Cag adds cagrilintide, an amylin analog, and the combination has no regulatory approval. That difference is why semaglutide carries grade A and Sema+Cag carries grade B on this store.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eHow is a two-peptide vial documented?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA combination vial needs documentation for each component. The Certificate of Analysis for a Sema+Cag lot should identify both semaglutide (about 4114 g\/mol) and cagrilintide (about 4409 g\/mol), typically by mass spectrometry, and report purity, typically by HPLC. The lot number and expiry date on the vial link it to that COA.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eWhat is the regulatory status of Sema+Cag?\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe combination is investigational. Novo Nordisk filed a New Drug Application for CagriSema with the FDA in December 2025 and, in September 2026, said it expects a decision in the fourth quarter of 2026. Any future approval would belong to the sponsor's branded product and would not extend to this PEPTYVA research vial.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eDocumentation\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eEach vial carries a PEPTYVA lot number and expiry date. The Certificate of Analysis for that lot can be requested through our contact page; for a two-component vial it should identify both semaglutide and cagrilintide. See Quality \u0026amp; Documentation for how to read a COA.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cstrong\u003eStorage and handling\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eKeep the unopened vial sealed in its original packaging, protected from light and heat, at the storage temperature printed on the PEPTYVA label. Check the strength, lot number and expiry date on arrival, and do not use material past the expiry date shown on the label.\u003c\/span\u003e\u003c\/p\u003e","brand":"Peptides Vallarta","offers":[{"title":"5 mg \/ B","offer_id":47106182021316,"sku":"PV-SEMACAG-5MG5MG","price":5060.0,"currency_code":"MXN","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/8424\/2884\/files\/Sema_Cag5mg5mg.jpg?v=1792953753","url":"https:\/\/peptidesvallarta.com\/es\/products\/sema-cag","provider":"Peptides Vallarta","version":"1.0","type":"link"}